US FDA panel backs booster shot for elderly, high risk groups

A US FDA advisory panel has endorsed a booster shot of Pfizer-BioNTech Covid-19 vaccine six months after full inoculation in people above 65 years and for individuals at high risk for severe disease

A US Food and Drug Administration (FDA) advisory panel has endorsed a booster shot of the Pfizer-BioNTech Covid-19 vaccine six months after full inoculation in people above 65 years and for individuals at high risk for severe disease.

The decision late Friday came after members of the FDA's Vaccines and Related Biological Products Advisory Committee voted against advising the agency to approve boosters for anyone 16 and older after hours of debate, reports Xinhua news agency.

Members of the committee expressed doubts about the safety of a booster dose in younger adults and teens, and said they wanted to see more data about the safety and long term efficacy of a booster dose.

 

A decision about boosters from the FDA is expected in the next few days.

Meanwhile, another advisory panel of the Centers for Disease Control and Prevention (CDC) is also scheduled to meet next week on how to apply the FDA's eventual decision and can fine-tune the recommendation.

President Joe Biden's administration have recently announced a plan to begin administering booster doses to the general population during the week of September 20, pending sign-offs from the FDA and CDC.

The CDC published data on Friday showing that all three Covid-19 vaccines available in the US -- Pfizer-BioNTech, Moderna and Johnson & Johnson -- still provide strong protection against hospitalisation.

Moderna's vaccine provided 93 per cent protection against hospitalisation, Pfizer's was 88 per cent and Johnson & Johnson's Janssen vaccine was 71 per cent, said the CDC study.

--IANS

ksk/